ClinicalTrials.gg
CompletedNCT00396097Updated Apr 5, 2016Results posted

Individualized, Target-Driven Treatment Of Children With Idiopathic Short Stature

A Phase 3 interventional study of Genotropin and Genotropin in Idiopathic Short Stature, sponsored by Pfizer. Completed at 43 sites in United States. Open to participants aged 3 Years to 10 Years. Per ClinicalTrials.gov, last updated 2016-04-05.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
316
Allocation
Randomized
Ages
3 Years to 10 Years
Sex
All
01

Study summary

To demonstrate that an individualized, formula-based Genotropin regimen for children with Idiopathic Short Stature will lead to a targeted height gain (to reach the target of 10th percentile (%), or -1.3 SDS) during 24 months of treatment. The endpoint at 4 years is to explore treatment efficiency over four years of two formula-based dose regimens (sub-arms) compared to standard treatment

02

Conditions studied

  • Idiopathic Short Stature

Keywords

  • ISS
  • human growth hormone
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 146 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years to 10 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Prepubertal children with bone ages between 3 and 10 years of age for males and 3 and 9 years of age for females
  • Naive to Growth Hormone treatment

Exclusion criteria

Exclusion Criteria:

  • Abnormal karyotype. Small Gestational Age and Skeletal dysplasia.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
316 participants (actual)

Study arms

  • Active comparator
    Standard

    Standard daily HGH treatment

    Drug: Genotropin

  • Active comparator
    Formula-based

    Formula-based dose regimen

    Drug: Genotropin

Interventions

  • Compare daily injections of formula-based HGH treatment to daily injections of standard HGH treatment in subjects with Idiopathic Short Stature over 24 months period followed by an exploratory 24 months period.

  • Compare daily injections of formula-based HGH treatment to daily injections of standard HGH treatment in subjects with Idiopathic Short Stature over 24 months period followed by an exploratory 24 months period.

06

What researchers measure

Primary outcomes

  1. Absolute On-target Difference (AOTD) at 24 Months

    This was defined as an absolute difference between the 24-month height standard deviation score (SDS) and targeted 24-month height SDS (10th percentile (%), or -1.3 SDS). SDS indicates how similar the participant was to the reference population. These were calculated using 2000 Center for the Disease Control (CDC) growth reference tables (by age and gender).

    Time frame: 2 years

Secondary outcomes

  1. Variability of Height SDS at 24 Months

    The continuous endpoint of variability of height SDS at 24 months was defined as the SD of the 24 month height SDS.

    Time frame: 2 years

  2. Time Cost (Months Until >= -2 SDS)

    Time cost was defined as the number of months needed until height SDS was within the normal limit (ie, \>= -2SDS).

    Time frame: 2 years

  3. Computed Cost of Height Gain at 48 Months

    The computed cost of height gain was defined as the amount of drug used relative to the observed height-gain, in terms of mg/cm, this was calculated at Month 48.

    Time frame: 4 years

  4. Estimated Cost of Height Gain Estimated Until Full Adult Height (FAH) at 48 Months

    The estimated cost of long-term height gain until FAH was calculated.

    Time frame: 4 years

  5. Change From Baseline in Height SDS at 48 Months.

    Change in height SDS was measured at 48 months.

    Time frame: 4 years

07

Results

Posted Nov 13, 2013

Participant flow

This was a 4-year, open-label, randomized study conducted at 40 centers across United States of America (USA). The first 2-years of the study constituted core phase and the last 2 years constituted the maintenance phase.

Participant flow — Overall Study
MilestoneStandard Dose ArmIndividualized Dose Arm
Started114202
Completed88156
Not completed2646
Withdrew: Withdrawal by subject1717
Withdrew: Lost to follow-up49
Withdrew: Other35
Withdrew: Protocol violation06
Withdrew: Adverse event15
Withdrew: Insufficient clinical response14

Outcome measures

PrimaryAbsolute On-target Difference (AOTD) at 24 Months

This was defined as an absolute difference between the 24-month height standard deviation score (SDS) and targeted 24-month height SDS (10th percentile (%), or -1.3 SDS). SDS indicates how similar the participant was to the reference population. These were calculated using 2000 Center for the Disease Control (CDC) growth reference tables (by age and gender).

Time frame:
2 years
Reported as:
Mean · Standard Deviation Score (SDS)
Absolute On-target Difference (AOTD) at 24 Months
Standard Deviation Score (SDS)Standard Dose ArmIndividualized Dose Arm
Absolute On-target Difference (AOTD) at 24 Months0.603 ± 0.29480.625 ± 0.3003
Statistical analysis
  • Standard Dose Arm vs Individualized Dose Arm · ANCOVA · p = 0.5762 · Mean difference (final values): -0.006
SecondaryVariability of Height SDS at 24 Months

The continuous endpoint of variability of height SDS at 24 months was defined as the SD of the 24 month height SDS.

Time frame:
2 years
Reported as:
Mean · Standard Deviation Score (SDS)
Variability of Height SDS at 24 Months
Standard Deviation Score (SDS)Standard Dose ArmIndividualized Dose Arm
Change from baseline at 24 months (n=101,184)1.12 ± 0.4081.11 ± 0.518
Change from baseline at 24 months LOCF (n=114,202)1.03 ± 0.4751.04 ± 0.544
Statistical analysis
  • Standard Dose Arm vs Individualized Dose Arm · ANOVA (Levene's Test) · p = 0.627
SecondaryTime Cost (Months Until >= -2 SDS)

Time cost was defined as the number of months needed until height SDS was within the normal limit (ie, \>= -2SDS).

Time frame:
2 years
Reported as:
Median · Months
Time Cost (Months Until >= -2 SDS)
MonthsStandard Dose ArmIndividualized Dose Arm
Time Cost (Months Until >= -2 SDS)12.00 (8.00 to 12.00)12.00 (8.00 to 12.00)
Statistical analysis
  • Standard Dose Arm vs Individualized Dose Arm · Regression, Cox · p = 0.8016 · Hazard ratio (hr): 1.033 · 95% CI 0.802 to 1.330
SecondaryComputed Cost of Height Gain at 48 Months

The computed cost of height gain was defined as the amount of drug used relative to the observed height-gain, in terms of mg/cm, this was calculated at Month 48.

Time frame:
4 years
Reported as:
Mean · mg/cm
Computed Cost of Height Gain at 48 Months
mg/cmStandard Dose ArmIndividualized Dose Arm OverallIndividualized Dose Arm 0.18 mg/kg/WeekIndividualized Dose Arm 0.24 mg/kg/Week
Computed Cost of Height Gain at 48 Months72.77 ± 17.91467.30 ± 24.38263.07 ± 21.65669.62 ± 21.903
Statistical analysis
  • Standard Dose Arm vs Individualized Dose Arm Overall · ANCOVA · p = 0.0101 · Mean difference (final values): 5.822 · 95% CI 1.395 to 10.249
  • Standard Dose Arm vs Individualized Dose Arm 0.18 mg/kg/Week · ANCOVA · p = 0.0002 · Mean difference (final values): 9.281 · 95% CI 4.417 to 14.145
  • Standard Dose Arm vs Individualized Dose Arm 0.24 mg/kg/Week · ANCOVA · p = 0.2001 · Mean difference (final values): 3.204 · 95% CI -1.707 to 8.114
SecondaryEstimated Cost of Height Gain Estimated Until Full Adult Height (FAH) at 48 Months

The estimated cost of long-term height gain until FAH was calculated.

Time frame:
4 years
Reported as:
Mean · mg/cm
Estimated Cost of Height Gain Estimated Until Full Adult Height (FAH) at 48 Months
mg/cmStandard Dose ArmIndividualized Dose Arm OverallIndividualized Dose Arm 0.18 mg/kg/WeekIndividualized Dose Arm 0.24/mg/kg/Week
Estimated Cost of Height Gain Estimated Until Full Adult Height (FAH) at 48 Months127.99 ± 29.70891.34 ± 31.85480.06 ± 21.00092.24 ± 25.213
Statistical analysis
  • Standard Dose Arm vs Individualized Dose Arm Overall · ANCOVA · p = <0.0001 · Mean difference (final values): 36.899 · 95% CI 30.181 to 43.618
  • Standard Dose Arm vs Individualized Dose Arm 0.18 mg/kg/Week · ANCOVA · p = <.0001 · Mean difference (final values): 48.517 · 95% CI 42.054 to 54.980
  • Standard Dose Arm vs Individualized Dose Arm 0.24/mg/kg/Week · ANCOVA · p = <.0001 · Mean difference (final values): 34.443 · 95% CI 27.936 to 40.951
SecondaryChange From Baseline in Height SDS at 48 Months.

Change in height SDS was measured at 48 months.

Time frame:
4 years
Reported as:
Mean · Standard Deviation Score (SDS)
Change From Baseline in Height SDS at 48 Months.
Standard Deviation Score (SDS)Standard Dose ArmIndividualized Dose Arm OverallIndividualized Dose Arm 0.18 mg/kg/WeekIndividualized Dose Arm 0.24 mg/kg/Week
Change From Baseline in Height SDS at 48 Months.1.33 ± 0.7171.24 ± 0.6681.33 ± 0.6371.34 ± 0.633
Statistical analysis
  • Standard Dose Arm vs Individualized Dose Arm Overall · ANCOVA · p = 0.2618 · Mean difference (final values): 0.091 · 95% CI -0.068 to 0.249
  • Standard Dose Arm vs Individualized Dose Arm 0.18 mg/kg/Week · ANCOVA · p = 0.8926 · Mean difference (final values): 0.013 · 95% CI -0.172 to 0.198
  • Standard Dose Arm vs Individualized Dose Arm 0.24 mg/kg/Week · ANCOVA · p = 0.9566 · Mean difference (final values): -0.005 · 95% CI -0.192 to 0.181

Adverse events

Collected over 4 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Standard Dose Arm—13/118 (11%)103/118 (87.3%)
Individualized Dose Arm—7/198 (3.5%)165/198 (83.3%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventStandard Dose ArmIndividualized Dose Arm
PneumoniaInfections and infestations2/1180/198
AsthmaRespiratory, thoracic and mediastinal disorders2/1180/198
Arnold-chiari malformationCongenital, familial and genetic disorders1/1180/198
Abdominal painGastrointestinal disorders1/1180/198
Intestinal obstructionGastrointestinal disorders1/1180/198
AppendicitisInfections and infestations1/1181/198
Postoperative wound infectionInfections and infestations1/1180/198
AccidentInjury, poisoning and procedural complications1/1180/198
Craniocerebral injuryInjury, poisoning and procedural complications1/1180/198
Facial bones fractureInjury, poisoning and procedural complications1/1180/198
Most frequent other events
Showing 10 of 27
Most frequent other events
EventStandard Dose ArmIndividualized Dose Arm
HeadacheNervous system disorders33/11859/198
Upper respiratory tract infectionInfections and infestations28/11845/198
Pharyngitis streptococcalInfections and infestations15/11830/198
InfluenzaInfections and infestations16/11822/198
CoughRespiratory, thoracic and mediastinal disorders8/11826/198
VomitingGastrointestinal disorders15/11821/198
ArthralgiaMusculoskeletal and connective tissue disorders15/11824/198
NasopharyngitisInfections and infestations8/11825/198
Pain in extremityMusculoskeletal and connective tissue disorders14/11817/198
Otitis mediaInfections and infestations11/11823/198

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Standard Dose ArmIndividualized Dose ArmTotal
Mean8.3 ± 2.18.4 ± 2.38.4 ± 2.2
Age, Customized
Age, Customized(Participants)Standard Dose ArmIndividualized Dose ArmTotal
<= 7 years3770107
>=7 years77132209
Sex: Female, Male
Sex: Female, Male(Participants)Standard Dose ArmIndividualized Dose ArmTotal
Female315889
Male83144227
08

Study locations

43 sites
  • Arkansas Children's Hospital
    Little Rock, Alaska 72202, United States
  • Arkansas Children's Hospital
    Little Rock, Arkansas 72202, United States
  • Children's Hospital of Los Angeles
    Los Angeles, California 90027, United States
  • Rady Children's Hospital - San Diego
    San Diego, California 32123-4282, United States
  • Pediatric Endocrinology of San Diego Medical Group Incorporated
    San Diego, California 92123, United States
  • Childrens Hospital Colorado
    Aurora, Colorado 80045, United States
  • Memorial Pediatric Specialty Clinic
    Colorado Springs, Colorado 80909, United States
  • Pediatric Endocrine Associates
    Greenwood Village, Colorado 80111, United States
  • Pediatric Endocrine Associates at The Longmont Clinic
    Longmont, Colorado 80501, United States
  • Joe DiMaggio Children's Hospital
    Hollywood, Florida 33021, United States
  • Miller School Of Medicine, University of Miami/Jackson Memorial Medical Center
    Miami, Florida 33136, United States
  • Pediatric Endocrinology Associates
    Miami, Florida 33155, United States
  • Arnold Palmer Hospital for Children
    Orlando, Florida 32806, United States
  • Nemours Children's Clinic
    Orlando, Florida 32806, United States
  • Nancy Wright, MD
    Tallahassee, Florida 32308, United States
  • University of Iowa Children's Hospital
    Iowa City, Iowa 52242, United States
  • University of Maryland Baltimore
    Baltimore, Maryland 21201, United States
  • Johns Hopkins Pediatric Endocrinology
    Baltimore, Maryland 21205, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Children's Hospital
    Boston, Massachusetts 02115, United States
  • Baystate Medical Center Children's Hospital
    Springfield, Massachusetts 01199, United States
  • Children's Mercy Hospital
    Kansas City, Missouri 64108, United States
  • Children's Endocrine Care of St. Louis, LLC
    St. Louis, Missouri 63141, United States
  • Saint Barnabas Ambulatory Care Center
    Livingston, New Jersey 07039, United States
  • Morristown Memorial Hospital
    Morristown, New Jersey 07962, United States
  • Children's Hospital at Montefiore
    Bronx, New York 10467-2490, United States
  • Maimonides Medical Center
    Brooklyn, New York 11219, United States
  • Women & Children's Hospital of Buffalo
    Buffalo, New York 14222, United States
  • The Steven and Alexandra Cohen Children's Medical Center of New York (CCMC)
    Lake Success, New York 11042, United States
  • Winthrop University Hospital
    Mineola, New York 11501, United States
  • Mount Sinai School of Medicine
    New York, New York 10029-6574, United States
  • Diabetes & Endocrine Center for Children & Young Adults at Phelps Memorial Hospital
    Sleepy Hollow, New York 10591, United States
  • The Research Institute at Nationwide Children's Hospital
    Columbus, Ohio 43205, United States
  • Central Ohio Pediatric Endocrinology/Diabetes Services (COPEDS)
    Columbus, Ohio 43235, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • Pediatric Alliance, PC
    Pittsburgh, Pennsylvania 15218, United States
  • Children's Hospital of Pittsburgh of UPMC
    Pittsburgh, Pennsylvania 15224, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • The Endocrine Clinic P.C.
    Memphis, Tennessee 38119, United States
  • Vanderbilt University
    Nashville, Tennessee 37232, United States
  • Ellen Sher, MD PA
    Dallas, Texas 75230, United States
  • Children's Medical Center
    Dallas, Texas 75235, United States
  • Cooks Children Medical Center/Dept. of Pediatric Endocrinology
    Fort Worth, Texas 76104, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2006, a primary completion of Aug 2012 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2013, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2006
First posted
Nov 6, 2006
Start
Dec 2006
Primary completionActual
Aug 2012
CompletionActual
Aug 2012
Results first posted
Nov 13, 2013
Last update
Apr 5, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 5, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00396097
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 6, 2006
Start date
Dec 2006
Primary completion
Aug 2012
Completion
Aug 2012
Results posted
Nov 13, 2013
Last update
Apr 5, 2016

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion